Research

Cellular

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.

StrongSupportsmedium confidence
recent trials show GLP-1RAs and dual GLP-1/GIPRA therapy accelerates FFM loss.
Zhenqi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2025

Why this rating

The claim is supported by recent trials mentioned in the abstract.

Source

Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review

Zhenqi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2025

DOI 10.1210/clinem/dgaf335

reviewCited 9×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →